Accuri Cytometers is a biotechnology startup founded in 2004 and headquartered in the United States. The company was acquired by BD and is now a wholly owned subsidiary. Accuri Cytometers addresses a critical need in the life sciences field, aiming to make flow cytometry more accessible to researchers. The startup recognizes the challenges researchers face, such as the high cost of instruments, software complexity, maintenance efforts, and space requirements. To tackle these issues, Accuri Cytometers has focused on creating an affordable, robust, and easy-to-use flow cytometer. The company's innovative approach is reflected in its engineering team, which has executed a ground-up design of a new instrument tailored to meet customer-driven specifications. Accuri Cytometers received a significant $6.00M Series E investment on 19 October 2010, with participation from notable investors including Arboretum Ventures, Baird Capital, F-Prime Capital, Flagship Pioneering, and InvestMichigan. This investment is a testament to the confidence these prominent investors have in the potential of Accuri Cytometers' innovative solution in the biotechnology, healthcare, and manufacturing industries.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Series E | $6.00M | 5 |
|
19 Oct 2010 |
| Series D | $4.00M | 6 |
|
10 Aug 2009 |
| Series C | $13.00M | 3 |
|
08 Jul 2008 |
| Venture Round | $2.00M | 1 |
|
29 Apr 2008 |
| Series B | $100.00K | - | 01 Sep 2007 |
No recent news or press coverage available for Accuri Cytometers.
We care about your data, and we'd love to use cookies make your experience better.
